{"id":"e82ad11d1e06","type":"article","url":"https://hartvaat.nl/2025/12/22/evinacumab-bij-kinderen-van-5-17-jaar-met-homozygote-familiaire-hypercholesterol/","title":"Evinacumab bij kinderen van 5-17 jaar met homozygote familiaire hypercholesterolemie","title_en":"Evinacumab in patients aged 5–17 years with homozygous familial hypercholesterolemia","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","internist"],"tags":["dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","ldl-cholesterol","lipoproteïne-a","statines","vrouwen","yellow-iii"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01525-4/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01525-4/fulltext","authors":["Robert S. Rosenson","Eliot A. Brinton","Daniel Gaudet","Frederick J. Raal","Carissa Baker-Smith","Patrick M. Moriarty","Susanne Greber-Platzer","Jean Bergeron","Brian W. McCrindle","Alpana Waldron","Shazia Ali","Richard T. George","Robert Pordy","Xue-Qiao Zhao","Albert Wiegman"],"significance":5,"published":"2025-12-22","source_date":"2025-12-22","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/","https://hartvaat.nl/kennis/lipiden/dutch-lipid-clinic-network-score/"],"congress":"","summary_en":"This study assessed the long-term efficacy and safety of evinacumab, an anti-ANGPTL3 antibody, in children and adolescents aged 5-17 years with homozygous familial hypercholesterolaemia. The findings support early advanced lipid-lowering therapy in this severe paediatric condition.","created":"2026-07-03T10:25:39Z","updated":"2026-07-03T13:25:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Kinderen met homozygote FH hebben geavanceerde lipidenverlagende therapie nodig. Deze studie beoordeelt de langetermijnwerkzaamheid en veiligheid van evinacumab, een nieuw anti-ANGPTL3-antilichaam, bij kinderen en adolescenten met HoFH.","abstract_original":"Children and adolescents with homozygous familial hypercholesterolemia (HoFH) routinely require advanced lipid-lowering therapies (LLTs). We assess the long-term efficacy and safety of evinacumab, a novel LLT, in children and adolescents with HoFH."}